This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients receiv
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence
β Scribed by Alfredo Marzano; Silvia Gaia; Valeria Ghisetti; Silvia Carenzi; Alberto Premoli; Wilma Debernardi-Venon; Carlo Alessandria; Alessandro Franchello; Mauro Salizzoni; Mario Rizzetto
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 108 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20402
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: The value of immunohistochemical methods to identify hepatitis C virus antigen (HCVAg) in liver tissue has not been established. We have evaluated the significance of HCVAg expression in livers of patients with transplants and recurrent hepatitis C virus (HCV) infection. Methods: Fo
Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT
H epatitis C virus (HCV) infection is a global health problem. The importance of HCV infection lies in its propensity to cause insidious and progressive liver damage, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The clinical and financial impact of HCV infection on this nati
## Abstract In this study, the longβterm (>3 years) efficacy of combination therapy for hepatitis B virus (HBV) recurrence and the associated factors were investigated. One hundred and sixtyβfive consecutive HBsAgβpositive patients (92 with liver cirrhosis, 73 with hepatocellular carcinoma; HCC) wh